A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05047094 |
|
Recruitment Status :
Recruiting
First Posted : September 16, 2021
Last Update Posted : May 20, 2024
|
Sponsor:
Alpha Tau Medical LTD.
Information provided by (Responsible Party):
Alpha Tau Medical LTD.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2026 |
| Estimated Study Completion Date : | June 2027 |